Recent Finacing
Recent Raise
Therini Bio is a clinical-stage biotech developing fibrin-targeting monoclonal antibodies (lead THN391) to selectively block fibrin-driven neuroinflammation while preserving coagulation, advancing into Phase 1b for AD and retinal disease.
